Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
New Horizons in Dyslipidaemia
Author(s): Peter Libby , Kausik Ray , Erik Stroes Start date: Feb 12, 2026
Join us forNew Horizons in Dyslipidaemia, a new one-day virtual educational event, taking place on 12 February 2026, designed for healthcare professionals involved in the management of cardiovascular risk and other lipid-related health conditions.This event will explore the rapidly evolving landscape of lipid management, addressing persistent gaps between perceived and actual cardiovascular risk… View more

Prevention & Chronic Conditions
ACC 2025: Lifetime Benefit by Control of Modifiable Risk Factors
Author(s): Christina Magnussen Added: 8 months ago
ACC 2025 - Individual-level data collected across 126 worldwide cohorts show controlling modifiable cardiovascular risk factors can potentially benefit life-years for freedom from CVD and death from any cause.Prof Christina Magnussen (University Heart and Vascular Centre Hamburg, Hamberg, DE) joins us onsite at ACC to discuss modifiable cardiovascular risk factors collected by the Global… View more

Cardiovascular Renal Metabolic
ESC 25 Guidelines Discussion: Management of Dyslipidaemias
Author(s): Harriette Van Spall , Jeanine Roeters Van Lennep Added: 2 months ago
ESC Congress 2025 - Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by Professor Jeanine Roeters van Lennep (Erasmus Medical Center, NL) to discuss the 2025 Focused Update of the 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias.This focused update delivers the most current, evidence-based recommendations for lipid management and cardiovascular risk… View more

Guidelines & Statements

Prevention & Chronic Conditions
AHA 25: Lp(a) and ASCVD: Translating Causal Evidence into Clinical Practice
Author(s): Michelle O'Donoghue Added: 1 month ago
AHA Scientific Sessions 2025 - Dr Michelle O'Donoghue (Brigham and Women's Hospital, US) joins us to discuss the evolving understanding of the causal relationship between elevated lipoprotein(a) and atherosclerotic cardiovascular disease, and what this means for risk stratification and management strategies in clinical practice.Dr O'Donoghue begins by highlighting the importance for clinicians to… View more

Cardiovascular Renal Metabolic

Prevention & Chronic Conditions
Research Area(s) / Expertise:
Kelvin Lee
Job title: Consultant Interventional Cardiologist
Prof Kelvin Lee is Consultant Interventional Cardiologist at the Lincolnshire Heart Centre with a focus on complex coronary intervention. His expertise includes intra-coronary imaging, rotational atherectomy, intravascular lithotripsy and coronary physiology using iFR and FFR. He leads the Cardiovascular Clinical Research Programme and is Cardio-Metabolic Lead and Deputy Clinical Director of… View more
Research Area(s) / Expertise:

Diabetes

 Job title: Attending Physician
Dr Chern-En Chiang is an Attending Physician at theTaipei Veterans General Hospital in Taipei, Taiwan. He gained his MD at the National Yang-Ming University School of Medicine, and studied his PhD at the same institution. His research interests include arrhythmias, hypertension, and hyperlipidemia. Dr Chern-En Chiang is a member of the editorial board for theJournal of Asian Pacific Society of… View more
Job title: Associate Professor of Internal Medicine-Hypertension
ESC 25: LipoaScreen: Cascade Screening for LP(a)
Author(s): Jonas Brinck Added: 3 months ago
ESC Congress 2025 - Cascade screening proves to be an effective tool to identify more patients with elevated LP(a) levels.Dr Jonas Brinck (Karolinska Institute, SE) joins us to discuss findings from the LipoaScreen study, evaluating cascade screening for elevated lipoprotein(a) in relatives of patients with atherosclerotic coronary artery disease.This prospective study examined whether elevated… View more

Imaging & Diagnostics

Prevention & Chronic Conditions
AHA 24: The LIBerate-HeFH_OLE Study
Author(s): Frederick Raal Added: 1 year ago
AHA Conference 2024 - Long-term safety and efficacy outcomes of lerodalcibep, a third generation PCSK9 inhibitor (LIB Therapeutics LLC), in heterozygous familial hypercholesterolemia (HoFH) subjects.Prof Frederick Raal (University of the Witwatersrand, ZA) joins us onsite at AHA Conference to discuss the findings from LIBerate-HeFH_OLE (NCT04798430; LIB Therapeutics).LIBerate-HeFH_OLE is an open… View more

Prevention & Chronic Conditions